nach oben

Current Nutrition Reports

Erschienen in:

04.05.2019 | Cancer (MF Leitzmann, Section Editor)

Vitamin D₃ from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality

verfasst von: William B. Grant, Meis Moukayed

Erschienen in: Current Nutrition Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarizes the understanding of vitamin D₃’s role in reducing risk of cancer incidence and mortality.

Recent Findings

Recent randomized clinical trials and observational studies of participants who took part in vitamin D₃ supplementation studies provide increasing evidence that concentrations of serum 25-hydroxyvitamin D₃ [25(OH)D₃] up to ~ 60 ng/ml are inversely correlated with all cancer and some specific cancers’ incidence and death, with a stronger effect on survival and death than on incidence. Mechanisms linking vitamin D₃ to effects on cellular proliferation, anti-angiogenesis, and anti-metastasis continue to be found.

Summary

Vitamin D₃ reduces cancer risk causally. Maintaining 25(OH)D₃ in the range of 40–60 ng/ml reduces the risk of many cancers. Raising 25(OH)D₃ concentrations after diagnosis to that range increases survival rates and could significantly reduce the global burden of cancer incidence and death.

Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 1980;9(3):227–31.CrossRefPubMed

Moukayed M, Grant WB. Molecular link between vitamin D and cancer prevention. Nutrients. 2013;5(10):3993–4021. https://doi.org/10.3390/nu5103993.CrossRefPubMedPubMedCentral

Grant WB. Roles of solar UVB and vitamin D in reducing cancer risk and increasing survival. Anticancer Res. 2016;36(3):1357–70.PubMed

Moukayed M, Grant WB. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: a review of the epidemiology, clinical trials, and mechanisms. Rev Endocr Metab Disord. 2017;18:167–82. https://doi.org/10.1007/s11154-017-9415-2.CrossRefPubMed

Grant WB. A review of the evidence supporting the vitamin D-cancer prevention hypothesis in 2017. Anticancer Res. 2018;38(2):1121–36. https://doi.org/10.21873/anticanres.12331.CrossRefPubMed

Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer. 2014;111(5):976–80. https://doi.org/10.1038/bjc.2014.294.CrossRefPubMedPubMedCentral

Grant WB. 25-Hydroxyvitamin D and breast cancer, colorectal cancer, and colorectal adenomas: case-control versus nested case-control studies. Anticancer Res. 2015;35(2):1153–60.PubMed

Maalmi H, Walter V, Jansen L, Chang-Claude J, Owen RW, Ulrich A, et al. Relationship of very low serum 25-hydroxyvitamin D3 levels with long-term survival in a large cohort of colorectal cancer patients from Germany. Eur J Epidemiol. 2017;32(11):961–71. https://doi.org/10.1007/s10654-017-0298-z.CrossRefPubMed

Feng Q, Zhang H, Dong Z, Zhou Y, Ma J. Circulating 25-hydroxyvitamin D and lung cancer risk and survival: a dose-response meta-analysis of prospective cohort studies. Medicine. 2017;96(45):e8613. https://doi.org/10.1097/MD.0000000000008613.CrossRefPubMedPubMedCentral

10.

Weinstein SJ, Mondul AM, Yu K, Layne TM, Abnet CC, Freedman ND, et al. Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival. Eur J Epidemiol. 2018;33(11):1087–99. https://doi.org/10.1007/s10654-018-0428-2.CrossRefPubMedPubMedCentral

11.

Grant WB, Boucher BJ, Bhattoa HP, Lahore H. Why vitamin D clinical trials should be based on 25-hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol. 2018;177:266–9. https://doi.org/10.1016/j.jsbmb.2017.08.009.CrossRefPubMed

12.

Goulao B, Stewart F, Ford JA, MacLennan G, Avenell A. Cancer and vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2018;107(4):652–63. https://doi.org/10.1093/ajcn/nqx047.CrossRefPubMed

13.

Zhang X, Niu W. An updated meta-analysis of randomized controlled trials on vitamin D supplement and cancer incidence and mortality (2018). https://ssrn.com/abstract=3273157.

14.

Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet. 2010;376(9736):180–8. https://doi.org/10.1016/S0140-6736(10)60588-0.CrossRefPubMedPubMedCentral

15.

Ong JS, Cuellar-Partida G, Lu Y, Fasching PA, Hein A, Burghaus S, et al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016;45(5):1619–30. https://doi.org/10.1093/ije/dyw207.CrossRefPubMedPubMedCentral

16.

Jiang X, Dimou NL, Al-Dabhani K, Lewis SJ, Martin RM, Haycock PC, et al. Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. Int J Epidemiol. 2018. https://doi.org/10.1093/ije/dyy284.

17.

Ong JS, Gharahkhani P, An J, Law MH, Whiteman DC, Neale RE, et al. Vitamin D and overall cancer risk and cancer mortality: a Mendelian randomization study. Hum Mol Genet. 2018;27(24):4315–22. https://doi.org/10.1093/hmg/ddy307.CrossRefPubMed

18.

Afzal S, Brondum-Jacobsen P, Bojesen SE, Nordestgaard BG. Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ. 2014;349:g6330. https://doi.org/10.1136/bmj.g6330.CrossRefPubMedPubMedCentral

19.

Grant WB. Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level: implications for meta-analyses and setting vitamin D guidelines. Dermato-endocrinology. 2011;3(3):199–204. https://doi.org/10.4161/derm.3.3.15364.CrossRefPubMedPubMedCentral

20.

•• Garland CF, Gorham ED. Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: a meta-analysis. J Steroid Biochem Mol Biol. 2017;168:1–8. https://doi.org/10.1016/j.jsbmb.2016.12.003 Provides additional evidence that colorecal cancer indicence is inversly correlated with 25(OH)D.CrossRefPubMed

21.

•• McDonnell SL, Baggerly CA, French CB, Baggerly LL, Garland CF, Gorham ED, et al. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations >/=60 vs <20 ng/ml (150 vs 50 nmol/L): pooled analysis of two randomized trials and a prospective cohort. PloS One. 2018;13(6):e0199265. https://doi.org/10.1371/journal.pone.0199265 An important observational study based on vitamin D supplementation and measurement of 25(OH)D.CrossRefPubMedPubMedCentral

22.

•• Madden JM, Duffy MJ, Zgaga L, Bennett K. Trends in vitamin D supplement use in a general female and breast cancer population in Ireland: a repeated cross-sectional study. PloS One. 2018;13(12):e0209033. https://doi.org/10.1371/journal.pone.0209033 Provides additional support that vitamin D supplementation improves cancer survival rates. CrossRefPubMedPubMedCentral

23.

Devesa SS, Grauman DJ, Blot WJ, Pennello GA, Hoover RN, Fraumeni JFJ. Atlas of cancer mortality in the United States, 1950-1994. NIH Publication No 99-4564 1999.

24.

Travis RC, Perez-Cornago A, Appleby PN, Albanes D, Joshu CE, Lutsey PL, et al. A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk. Cancer Res. 2019;79(1):274–85. https://doi.org/10.1158/0008-5472.CAN-18-2318.CrossRefPubMed

25.

DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66(4):290–308. https://doi.org/10.3322/caac.21340.CrossRefPubMed

26.

•• Batai K, Murphy AB, Ruden M, Newsome J, Shah E, Dixon MA, et al. Race and BMI modify associations of calcium and vitamin D intake with prostate cancer. BMC Cancer. 2017;17(1):64. https://doi.org/10.1186/s12885-017-3060-8 Provides additional information to help understand the roles of vitamin D and calcium in risk of prostate cancer. CrossRefPubMedPubMedCentral

27.

Fedirko V, Duarte-Salles T, Bamia C, Trichopoulou A, Aleksandrova K, Trichopoulos D, et al. Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology. 2014;60(4):1222–30. https://doi.org/10.1002/hep.27079.CrossRefPubMed

28.

Budhathoki S, Hidaka A, Yamaji T, Sawada N, Tanaka-Mizuno S, Kuchiba A, et al. Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan public health center-based prospective study cohort. BMJ. 2018;360:k671. https://doi.org/10.1136/bmj.k671.CrossRefPubMedPubMedCentral

29.

Zhao J, Wang H, Zhang Z, Zhou X, Yao J, Zhang R, et al. Vitamin D deficiency as a risk factor for thyroid cancer: a meta-analysis of case-control studies. Nutrition. 2019;57:5–11. https://doi.org/10.1016/j.nut.2018.04.015.CrossRefPubMed

30.

Deuster E, Jeschke U, Ye Y, Mahner S, Czogalla B. Vitamin D and VDR in gynecological cancers-a systematic review. Int J Mol Sci. 2017;18(11). https://doi.org/10.3390/ijms18112328.

31.

Guo H, Guo J, Xie W, Yuan L, Sheng X. The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention. J Ovarian Res. 2018;11(1):71. https://doi.org/10.1186/s13048-018-0443-7.CrossRefPubMedPubMedCentral

32.

Zhang X, Huang X-Z, Chen W-J, Wu J, Chen Y, Wu C-C, et al. Plasma 25-hydroxyvitamin D levels, vitamin D intake, and pancreatic risk or mortality: a meta-analysis. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.18888.

33.

•• McDonnell SL, Baggerly C, French CB, Baggerly LL, Garland CF, Gorham ED, et al. Serum 25-hydroxyvitamin D concentrations >/=40 ng/ml are associated with >65% lower cancer risk: pooled analysis of randomized trial and prospective cohort study. PloS One. 2016;11(4):e0152441. https://doi.org/10.1371/journal.pone.0152441 An important observational study based on vitamin D supplementation and measurement of 25(OH)D.CrossRefPubMedPubMedCentral

34.

Cheney CP, Thorand B, Huth C, Berger K, Peters A, Seifert-Klauss V, et al. The association between serum 25-hydroxyvitamin D and cancer risk: results from the prospective KORA F4 study. Oncol Res Treat. 2018;41(3):117–21. https://doi.org/10.1159/000485512.CrossRefPubMed

35.

•• Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. https://doi.org/10.1056/NEJMoa1809944 The largest vitamin D RCT to date, with important findings from secondary analyses buried in the tables.CrossRefPubMed

36.

Drincic AT, Armas LA, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity (Silver Spring). 2012;20(7):1444–8. https://doi.org/10.1038/oby.2011.404.CrossRef

37.

Scott JF, Das LM, Ahsanuddin S, Qiu Y, Binko AM, Traylor ZP, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137(10):2078–86. https://doi.org/10.1016/j.jid.2017.04.040.CrossRefPubMedPubMedCentral

38.

Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 2012;441(1):61–76. https://doi.org/10.1042/BJ20110744.CrossRefPubMed

39.

Wang G, Lei L, Zhao X, Zhang J, Zhou M, Nan K. Calcitriol inhibits cervical cancer cell proliferation through downregulation of HCCR1 expression. Oncol Res. 2014;22(5–6):301–9. https://doi.org/10.3727/096504015X14424348425991.CrossRefPubMed

40.

Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001;15(8):1370–80. https://doi.org/10.1210/mend.15.8.0673.CrossRefPubMed

41.

Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene. 2004;23(19):3350–60. https://doi.org/10.1038/sj.onc.1207461.CrossRefPubMed

42.

Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP. The anti-proliferative effects of 1alpha, 25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 2000;19(44):5091–7. https://doi.org/10.1038/sj.onc.1203888.CrossRefPubMed

43.

Salehi-Tabar R, Nguyen-Yamamoto L, Tavera-Mendoza LE, Quail T, Dimitrov V, An BS, et al. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A. 2012;109(46):18827–32. https://doi.org/10.1073/pnas.1210037109.CrossRefPubMedPubMedCentral

44.

Bi X, Shi Q, Zhang H, Bao Y, Hu D, Pohl N, et al. c-Jun NH2-teminal kinase 1 interacts with vitamin D receptor and affects vitamin D-mediated inhibition of cancer cell proliferation. J Steroid Biochem Mol Biol. 2016;163:164–72. https://doi.org/10.1016/j.jsbmb.2016.05.009.CrossRefPubMed

45.

Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 2000;60(8):2304–12.PubMed

46.

Baudet C, Chevalier G, Chassevent A, Canova C, Filmon R, Larra F, et al. 1,25-Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line. J Neurosci Res. 1996;46(5):540–50. https://doi.org/10.1002/(SICI)1097-4547(19961201)46:5<540::AID-JNR3>3.0.CO;2-J.CrossRefPubMed

47.

Kasiappan R, Shen Z, Tse AK, Jinwal U, Tang J, Lungchukiet P, et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. J Biol Chem. 2012;287(49):41297–309.CrossRefPubMedPubMedCentral

48.

•• Bandera Merchan B, Morcillo S, Martin-Nunez G, Tinahones FJ, Macias-Gonzalez M. The role of vitamin D and VDR in carcinogenesis: through epidemiology and basic sciences. J Steroid Biochem Mol Biol. 2017;167:203–18. https://doi.org/10.1016/j.jsbmb.2016.11.020 An excellent review of the roles of vitamin D and VDR in carcinogenesis.CrossRefPubMed

49.

Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98. https://doi.org/10.3389/fimmu.2011.00098.CrossRefPubMed

50.

Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20(1):65–71. https://doi.org/10.1016/j.gde.2009.11.004.CrossRefPubMed

51.

Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90. https://doi.org/10.1016/j.cell.2009.11.007.CrossRefPubMed

52.

Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21(14):1714–9. https://doi.org/10.1101/gad.1549407.CrossRefPubMedPubMedCentral

53.

Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002;33(2):213–9.CrossRefPubMed

54.

Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12(8):715–23. https://doi.org/10.1038/ni.2060.CrossRefPubMed

55.

Aggarwal BB, Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr Opin Pharmacol. 2009;9(4):351–69. https://doi.org/10.1016/j.coph.2009.06.020.CrossRefPubMedPubMedCentral

56.

Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 2006;20(18):2527–38. https://doi.org/10.1101/gad.1455706.CrossRefPubMedPubMedCentral

57.

Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342–57. https://doi.org/10.1038/nrc3691.CrossRefPubMed

58.

•• Jeon SM, Shin EA. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):20. https://doi.org/10.1038/s12276-018-0038-9 A very good recent review.CrossRefPubMedCentral

59.

Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 2006;66(8):4516–24. https://doi.org/10.1158/0008-5472.CAN-05-3796.CrossRefPubMed

60.

Bao BY, Yeh SD, Lee YF. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis. 2006;27(1):32–42. https://doi.org/10.1093/carcin/bgi170.CrossRefPubMed

61.

Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009;28(44):3892–902.CrossRefPubMedPubMedCentral

62.

•• Liu W, Zhang L, Xu HJ, Li Y, Hu CM, Yang JY, et al. The anti-inflammatory effects of vitamin D in tumorigenesis. Int J Mol Sci. 2018;19(9). https://doi.org/10.3390/ijms19092736.

63.

Ma Y, Johnson CS, Trump DL. Mechanistic insights of vitamin D anticancer effects. Vitam Horm. 2016;100:395–431. https://doi.org/10.1016/bs.vh.2015.11.003.CrossRefPubMed

64.

Ma Y, Yu WD, Su B, Seshadri M, Luo W, Trump DL, et al. Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1alpha,25-dihydroxycholecalciferol. Cancer. 2013;119(3):563–74. https://doi.org/10.1002/cncr.27531.CrossRefPubMed

65.

Alvarez-Dolado M, Gonzalez-Sancho JM, Navarro-Yubero C, Garcia-Fernandez LF, Munoz A. Retinoic acid and 1,25-dihydroxyvitamin D3 inhibit tenascin-C expression in rat glioma C6 cells. J Neurosci Res. 1999;58(2):293–300.CrossRefPubMed

66.

Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A. 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 1998;426(2):225–8.CrossRefPubMed

67.

Vanoirbeek E, Eelen G, Verlinden L, Carmeliet G, Mathieu C, Bouillon R, et al. PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D. Oncogene. 2014;33(15):1904–11. https://doi.org/10.1038/onc.2013.123.CrossRefPubMed

68.

Garimella R, Tadikonda P, Tawfik O, Gunewardena S, Rowe P, Van Veldhuizen P. Vitamin D impacts the expression of Runx2 target genes and modulates inflammation, oxidative stress and membrane vesicle biogenesis gene networks in 143B osteosarcoma cells. Int J Mol Sci. 2017;18(3). https://doi.org/10.3390/ijms18030642.

69.

•• Tavera-Mendoza LE, Westerling T, Libby E, Marusyk A, Cato L, Cassani R, et al. Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells. Proc Natl Acad Sci U S A. 2017;114(11):E2186–E94. https://doi.org/10.1073/pnas.1615015114 Shows how vitamin D regulates autophagy in breast cancer cells.CrossRefPubMedPubMedCentral

70.

Dimitrov V, Bouttier M, Boukhaled G, Salehi-Tabar R, Avramescu RG, Memari B, et al. Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem. 2017;292(50):20657–68. https://doi.org/10.1074/jbc.M117.793885.CrossRefPubMedPubMedCentral

71.

Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. J Cancer. 2010;1:101–7.CrossRefPubMedPubMedCentral

72.

Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, et al. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle. 2010;9(15):3022–9. https://doi.org/10.4161/cc.9.15.12381.CrossRefPubMedPubMedCentral

73.

Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer. 2010;116(13):3294–303. https://doi.org/10.1002/cncr.25059.CrossRefPubMed

74.

Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, et al. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther. 2008;7(9):3047–55. https://doi.org/10.1158/1535-7163.MCT-08-0243.CrossRefPubMedPubMedCentral

Titel: Vitamin D3 from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality
verfasst von: William B. Grant
Meis Moukayed
Publikationsdatum: 04.05.2019
Verlag: Springer US
Erschienen in: Current Nutrition Reports / Ausgabe 3/2019
Elektronische ISSN: 2161-3311
DOI: https://doi.org/10.1007/s13668-019-0262-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Vitamin D₃ from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Does Alcohol Use Affect Cancer Risk?

The Impact of Diet on Breast Cancer Outcomes

Nutrition and Metabolic Profiles in the Natural History of Dementia: Recent Insights from Systems Biology and Life Course Epidemiology

Nutritional Metabolomics in Cancer Epidemiology: Current Trends, Challenges, and Future Directions

Food and Beverage Price Promotions: an Untapped Policy Target for Improving Population Diets and Health

The Endocrine Role of Bone in Cardiometabolic Health

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin